Exchange: NYSE
Industry: Drug Manufacturers/Other
Last Trade: 4:03 PM ET 2/9/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.48 | 1.26 | 17.46 |
| EPS, GAAP | 1.33 | 1.17 | 13.68 |
| Consensus Estimate | 1.29 | 1.33 | -3.01 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | NA | 5.32 | NA |
| EPS, GAAP | 5.40 | 4.31 | 25.29 |
| Consensus Estimate | NA | NA | NA |
| NVO | Industry Average | |
| P/E (TTM) | 25.04 | 29.50 |
| P/E (Forward) | 22.69 | 13.00 |
| PEG Ratio | 1.44 | 2.45 |
| Price/Sales | NA | 4.56 |
| Beta | 0.54 | 0.77 |
| 10:34 AM | 2/2/2012 | Novo Nordisk Raises Guidance As Earnings Beat Views |
| 6:38 AM | 2/2/2012 | Novo Nordisk May Perform Stock Split - Chief Financial Officer |
| 2/6/2012 | These stocks just rolled over. Can they come back? (The Motley Fool) |
| 1/30/2012 | Third time's the charm for Amylin's Bydureon. (The Motley Fool) |
| 1/30/2012 | Stocks in the Spotlight Monday (Barrons.com) |
| 1/27/2012 | FDA Approves Amylin's Diabetes Drug (WSJ.com) |
| 1/27/2012 | Amylin Soars on Bydureon Aproval (Barrons.com) |
| 1/25/2012 | 5 Big Drugs for 2012 (Barrons.com) |
| 1/18/2012 | A.M. Vitals: Pfizer, Medivation End Dimebon Development (WSJ.com) |
| 1/17/2012 | Celebrity Chef Becomes Pitchwoman for Diabetes Drug (WSJ.com) |
![[sm0212smart]](http://s.wsj.net/public/resources/images/PF-AB863_sm0212_C_20120118122431.jpg)
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
